rs869025631
Variant summary
Our verdict is Pathogenic. The variant received 15 ACMG points: 15P and 0B. PM1PM2PM5PP3PP5_Very_Strong
The NM_000551.4(VHL):c.332G>A(p.Ser111Asn) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S111I) has been classified as Uncertain significance.
Frequency
Consequence
NM_000551.4 missense
Scores
Clinical Significance
Conservation
Publications
- pheochromocytomaInheritance: AD Classification: DEFINITIVE Submitted by: G2P
- von Hippel-Lindau diseaseInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, Orphanet
- renal cell carcinomaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- autosomal recessive secondary polycythemia not associated with VHL geneInheritance: AR Classification: STRONG Submitted by: Ambry Genetics
- Chuvash polycythemiaInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 15 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| VHL | NM_000551.4 | c.332G>A | p.Ser111Asn | missense_variant | Exon 1 of 3 | ENST00000256474.3 | NP_000542.1 | |
| VHL | NM_001354723.2 | c.332G>A | p.Ser111Asn | missense_variant | Exon 1 of 3 | NP_001341652.1 | ||
| VHL | NM_198156.3 | c.332G>A | p.Ser111Asn | missense_variant | Exon 1 of 2 | NP_937799.1 | ||
| VHL | NR_176335.1 | n.402G>A | non_coding_transcript_exon_variant | Exon 1 of 4 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1446050Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 719814
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:2
Variant summary: This c.332G>A variant affects a conserved nucleotide, resulting in amino acid change from Ser to Asn. Although 4/4 in-silico tools predict this variant to be benign, no functional studies have been performed to confirm these predictions. This variant was not found in approximately 92088 control chromosomes including the broad and large populations from ExAC. In literature, the variant has been widely reported as a pathogenic variant found in several patients/families with VHL disease, including somatic occurrences. This p.Ser111 is likely to be a mutational hot-spot where other likely pathogenic variant [such as p.S111R (c.331A>C and c.333C>G), p.S111C, p.S111I, etc.] have also been reported. At least one reputable database classifies the variant as pathogenic. Taken together, this variant has been classified as a Pathogenic. -
- -
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
This variant disrupts the p.Ser111 amino acid residue in VHL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7728151, 12114495, 16868829, 22071692, 25562111; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. ClinVar contains an entry for this variant (Variation ID: 223186). This missense change has been observed in individuals with von Hippel-Lindau syndrome (PMID: 7728151, 27527340, 28849724). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 111 of the VHL protein (p.Ser111Asn). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.S111N mutation (also known as c.332G>A) is located in exon 1 of the VHL gene. This alteration results from a G to A substitution at nucleotide position 332. The serine at codon 111 is replaced by asparagine, an amino acid with similar properties. This mutation has been reported in many VHL families affected with retinal angiomas, CNS hemangioblastomas, and renal cell carcinoma. None of the families in the literature had a history of pheochromocytomas which would fit the clinical description of VHL Type 1 (Chen et al. Human Mutation. 1995. 5:66-75; Maher et al. J Med Genet. 1996: 33328-332; Zbar et al. Human Mutation. 1996. 8:348-357; Ong et al. Human Mutation. 2007. 28(2):143-149; Zhang et al. J Cancer Res Clin Oncol. 2008. 134:1211-1218). Based on the available evidence, p.S111N is classified as a pathogenic mutation. This mutation has been referred to as p.S182N (c.545G>A) in older literature. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at